What does this research mean for the field?

Sub-anesthetic doses of etomidate can effectively and safely control severe hypercortisolism preoperatively in patients with adrenocortical carcinoma who are intolerant to mitotane. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To describe the use of sub-anesthetic etomidate monotherapy for rapid perioperative control of severe hypercortisolism in a mitotane-intolerant patient with adrenocortical carcinoma.

September 8, 2026CureusOpen Access

Etomidate Monotherapy for Perioperative Control of Hypercortisolism in a Mitotane-Intolerant Patient With Adrenocortical Carcinoma: A Case Report

View Full Paper

Ask AI

Bookmark

Authors

NANaeem Alkheamy JJJalal Jbara NSNissar Shaikh

Discussion

Member takes

Overview

Case report demonstrates rapid hypercortisolism control using sub-anesthetic etomidate in a mitotane-intolerant patient with adrenocortical carcinoma, highlighting its utility as a surgical bridge.

Key Points

To describe the use of sub-anesthetic etomidate monotherapy for rapid perioperative control of severe hypercortisolism in a mitotane-intolerant patient with adrenocortical carcinoma.
Clinical evaluation and management of a 34-year-old male with ACTH-independent Cushing syndrome and right adrenal adenocarcinoma confirmed by MRI and PET imaging.
Implementation of continuous sub-anesthetic etomidate infusion as bridging therapy prior to definitive surgical resection after failure of mitotane treatment.
Sub-anesthetic etomidate therapy markedly lowered elevated circulating cortisol levels.
Treatment successfully controlled blood pressure and reduced the need for potassium repletion with minimal adverse effects.

Cite This Study

Alkheamy et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd72a58e84d0ff5b45b60 https://doi.org/10.7759/cureus.115808

View Full Paper

Ask AI

Bookmark

September 8, 2026CureusOpen Access

Etomidate Monotherapy for Perioperative Control of Hypercortisolism in a Mitotane-Intolerant Patient With Adrenocortical Carcinoma: A Case Report

View Full Paper

Ask AI

Bookmark

Authors

NANaeem Alkheamy JJJalal Jbara NSNissar Shaikh

Discussion

Member takes

Overview

Case report demonstrates rapid hypercortisolism control using sub-anesthetic etomidate in a mitotane-intolerant patient with adrenocortical carcinoma, highlighting its utility as a surgical bridge.

Key Points

To describe the use of sub-anesthetic etomidate monotherapy for rapid perioperative control of severe hypercortisolism in a mitotane-intolerant patient with adrenocortical carcinoma.
Clinical evaluation and management of a 34-year-old male with ACTH-independent Cushing syndrome and right adrenal adenocarcinoma confirmed by MRI and PET imaging.
Implementation of continuous sub-anesthetic etomidate infusion as bridging therapy prior to definitive surgical resection after failure of mitotane treatment.
Sub-anesthetic etomidate therapy markedly lowered elevated circulating cortisol levels.
Treatment successfully controlled blood pressure and reduced the need for potassium repletion with minimal adverse effects.

Cite This Study

Alkheamy et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd72a58e84d0ff5b45b60 https://doi.org/10.7759/cureus.115808

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark